Author Archives: Marta Figueiredo PhD

FDA Grants Rare Pediatric Disease Designation to Anavex 2-73 for Rett Syndrome

The U.S. Food and Drug Administration (FDA) has granted rare pediatric disease designation to Anavex 2-73 (blarcamesine) for the treatment of Rett syndrome. This designation provides priority review to investigational treatments that have the potential to provide clinically meaningful benefits in serious rare diseases mainly affecting individuals younger than 18. If…